Tolerance of Liver Transplant Patients to Strenuous Physical Activity in High-Altitude

Jacques Pirenne(Universitair Ziekenhuis Leuven), Benoît Pirotte(Erasmus Hospital), Luc Vanhees(Unknown), M. Häuser(University Hospital of Lausanne), F. Noizat‐Pirenne(Inserm), T Kharkevitch(UCB Pharma (Belgium)), Willy Peetermans(KU Leuven), Etienne Hamoir(University of Liège), Frederik Nevens(KU Leuven), Hiroaki Kitade(Kansai Medical University), Yves Devos(KU Leuven), F Van Gelder(KU Leuven), Chris Verslype(Universitair Ziekenhuis Leuven)
American Journal of Transplantation
April 1, 2004
10.1111/j.1600-6143.2004.00363.x
Cited by 33

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k